Alembic Pharmaceuticals' branded business Ex-Azithromycin has shown a growth of 8% and 14% in April 2022 and May 2022 respectively despite degrowth shown by the Indian Pharmaceutical Market (IPM). 

The Indian Pharmaceutical Market for April 2022 and May 2022 has shown de-growth of 9% and 6% whereas Alembic Pharmaceuticals has shown a degrowth of 8% and 12% respectively due to anti-infective segment having higher base in April 2021 and May 2021 (Second Covid wave effect) which got normalized in April 2022 and May 2022.

 The company's speciality segments continue to show a robust momentum on the back of enhanced operational momentum and strong new product launches.